戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 COPD," and 1,590 (38.8%) as "unaffected" (no obstructive airway disease).
2  to the later development or exacerbation of obstructive airway disease.
3 induced bronchoconstriction in patients with obstructive airway disease.
4  in mortality and morbidity in patients with obstructive airway disease.
5 y improved oxygenation only in patients with obstructive airway disease.
6 oids and 2.1 (95% CI, 2.1-2.1) for drugs for obstructive airway disease.
7 etation of imaging findings in patients with obstructive airway disease.
8 diseases, vascular inflammation, and chronic obstructive airway disease.
9 suggest therapeutic approaches to asthma and obstructive airway disease.
10  therapeutic potential for the management of obstructive airway disease.
11 tially important therapeutic implications in obstructive airway diseases.
12 otentially important therapeutic targets for obstructive airway diseases.
13 ae seropositivity and both acute and chronic obstructive airway diseases.
14 s attain a hypercontractile phenotype during obstructive airway diseases.
15 ar changes occur early in the development of obstructive airways disease.
16 hat is up-regulated in patients with chronic obstructive airways disease.
17  [12%] deaths), mainly pneumonia and chronic obstructive airways disease.
18 as well as non-CF bronchiectasis and chronic obstructive airways disease.
19 le asthma," 1,996 (31.1%) as "unclassifiable obstructive airway disease," 228 (3.5%) as "COPD," and 2
20 d 42.8% of the facial mask group) or chronic obstructive airway disease (34.3% of the nasal mask grou
21 le asthma," 1,193 (29.1%) as "unclassifiable obstructive airway disease, " 626 (15.3%) as "COPD," and
22 /2 years) and in 15 control patients without obstructive airway disease (age range, 2 months to 7 yea
23 ceptor agonists are used in the treatment of obstructive airway disease and overactive bladder syndro
24 c syndrome-related conditions, inhalants for obstructive airway diseases and glucocorticoid use.
25  phenotyping can help in understanding these obstructive airway diseases and provide guidance for dis
26 cardiopulmonary conditions, including severe obstructive airways disease and left ventricular dysfunc
27 he 6 diagnoses (congestive heart failure and obstructive airways disease) and similar for the other 4
28 a link between early antibiotic exposure and obstructive airway disease, but corresponding data for p
29 hanges recapitulate aspects of complex human obstructive airway diseases, but their molecular mechani
30 matics (A; n = 5), and patients with chronic obstructive airway disease (COPD; n = 10).
31                       Weight loss in chronic obstructive airways disease (COPD) is associated with an
32 eover, they stipulated that the phenotype of obstructive airway disease could be affected by sex and
33 se, spontaneous pneumothorax associated with obstructive airway disease from chronic GVHD after bone
34 s' call to carefully phenotype patients with obstructive airways diseases has been adopted by many cu
35 ng function and an increased risk of chronic obstructive airway disease in adulthood.
36 for sudden fetal and infant death as well as obstructive airway disease in childhood.
37 ndings give unique insight into the cause of obstructive airways disease in 18-year-olds, and follow-
38                         It is useful in many obstructive airway diseases, including obliterative bron
39 portunity to describe the latency period for obstructive airway disease (OAD) diagnoses.
40 n the allograft rejection that characterizes obstructive airway disease (OAD).
41              Neither the association between obstructive airways disease (OAD) and sleep apnea-hypopn
42                      This study included non-obstructive airways disease (OAD) controls (n = 19), a C
43 itants of New York City to WTC-PM and caused obstructive airways disease (OAD), gastroesophageal refl
44                         Use of inhalants for obstructive airway diseases (PR = 0.79; 95% CI = 0.74-0.
45 chanisms that exaggerate mucin production in obstructive airway diseases remain unknown.
46 rt disease, cerebrovascular disease, chronic obstructive airways disease, sex, or treatment method.
47 us hypersecretion is an important feature of obstructive airway diseases such as asthma, chronic obst
48                        Exacerbations of muco-obstructive airway diseases such as COPD and asthma are
49 d natural history of imminent pediatric muco-obstructive airway diseases such as cystic fibrosis rema
50  upregulated in the airways of subjects with obstructive airway diseases, to its unique GPCR CCR6 ind
51      Subsequent mortality and medication for obstructive airway disease were ascertained at 5-yr foll
52 and provisional diagnoses of restrictive and obstructive airway disease were assigned based on percen